2001
DOI: 10.1039/b101327k
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of 6-substituted purin-2-ones with potential cytokinin activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
10
0

Year Published

2001
2001
2016
2016

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 18 publications
(11 citation statements)
references
References 29 publications
1
10
0
Order By: Relevance
“…The exception to this generalization is the unusually potent Complex I inhibition by 58, 73, and 75 where the piericidin A1 side chain (but not farnesyl) appears to compensate for their removal (Figure 4). Significantly, the series of analogues bearing the farnesyl side chain exhibit trends consistent with expectations of a simple coenzyme Q mimic where both the C4' hydroxyl group and the C5' methyl group each increase either the Complex I inhibition or L1210 cytotoxicity approximately 30-100 fold with the former target-based assay (Complex I) assay exhibiting IC 50 's approximately 10-fold lower than the cell-based (L1210) assay. In marked contrast, the series bearing the piericidin A1 side chain exhibited much smaller 1-2.5 fold losses in Complex I activity with removal of either the C4' hydroxyl or C5' methyl group, while experiencing even greater 200-500 losses in cytotoxic activity in the cellular assay.…”
Section: Compound Assessmentssupporting
confidence: 61%
“…The exception to this generalization is the unusually potent Complex I inhibition by 58, 73, and 75 where the piericidin A1 side chain (but not farnesyl) appears to compensate for their removal (Figure 4). Significantly, the series of analogues bearing the farnesyl side chain exhibit trends consistent with expectations of a simple coenzyme Q mimic where both the C4' hydroxyl group and the C5' methyl group each increase either the Complex I inhibition or L1210 cytotoxicity approximately 30-100 fold with the former target-based assay (Complex I) assay exhibiting IC 50 's approximately 10-fold lower than the cell-based (L1210) assay. In marked contrast, the series bearing the piericidin A1 side chain exhibited much smaller 1-2.5 fold losses in Complex I activity with removal of either the C4' hydroxyl or C5' methyl group, while experiencing even greater 200-500 losses in cytotoxic activity in the cellular assay.…”
Section: Compound Assessmentssupporting
confidence: 61%
“…Product 86 was obtained in 48% yield by exposing the monomer as an oil to daylight irradiation. 190 Dimerization of styryl-substituted 2,3-dicyanopyrazines led to products like 87 , which are of interest in the context of new fluorescent materials. 191 In all cases shown in Figure 5 , the photodimerization occurred vertically (i.e., with a preference for the HT dimer in the trans-syn-trans configuration).…”
Section: Direct Excitation and Sensitizationmentioning
confidence: 99%
“…The aqueous phase was extracted with EtOAc (2 ϫ 40 mL). The combined EtOAc extracts were dried (MgSO 4 ) and evaporated under reduced pressure, and the crude product was purified by flash chromatography on silica gel eluting with hexane-EtOAc (95:5) followed by hexaneEtOAc-CH 2 …”
Section: -Phenylmethyl-9-(tetrahydro-2h-pyran-2-yl)-9h-purine 3amentioning
confidence: 99%